Post by Debiopharm

A week after #ENDO2026, a few moments and conversations continue to resonate.✨ From the crisp Chicago morning air during the Endocrine Society 5K fun run to engaging discussions across the congress, this year once again highlighted the strength of the endocrine community. We were pleased to present our poster on patient-reported outcomes, with a focus on quality of life, with Debio 4126. One message clearly stood out: 👉 the ongoing burden of treatment for patients living with acromegaly. Exploring what a 12-week treatment interval could mean from the patient perspective — including treatment satisfaction and quality of life — remains an important step forward. 📌 For those who couldn’t attend ENDO, you can access the poster here:  https://lnkd.in/evr5xdFc 🙏 Thank you to all investigators, collaborators, and especially the patients who make this research possible. #ENDO2026 #Acromegaly #Endocrinology #ClinicalResearch #QualityOfLife 📸 Isabelle Delattre Petit, J D Faccinetti, Patricia Comola Lepetit, Anne Vaslin Chessex, Simona Ispas-Jouron